Hannan Tabiha Binte, Paul Shrebash, Khan Md Mohiuddin, Bhattacharjee Binayak, Abedin Md Zainal, Tarafder Pritish, Al-Amin T M, Amin Muhammad Abdullah Al, Rahman Md Sayedur, Chowdhury Fazle Rabbi
Bangabandhu Sheikh Mujib Medical University, Department of Internal Medicine, Dhaka, Bangladesh.
Mymensingh Medical College Hospital, Department of Medicine, Mymensingh, Bangladesh.
IJID Reg. 2024 May 31;12:100381. doi: 10.1016/j.ijregi.2024.100381. eCollection 2024 Sep.
Irrational and injudicious use of antibiotics in COVID-19 patients could be detrimental in a tropical country with a weak antibiotic stewardship policy such as Bangladesh. This study aimed to focus on the antibiotic usage patterns in COVID-19 patients in Bangladesh.
This prospective observational study was performed from July 2020 to June 2021 in five tertiary hospitals in Bangladesh. Data on demographic profile, disease severity, and antibiotic usage were collected directly from the patients' hospital documents.
A total of 3486 (94.4%) patients were treated with at least one antibiotic; 3261 (93.6%) patients received a single antibiotic, and 225 (6.5%) received multiple antibiotics. The most used antibiotics were ceftriaxone (37.3%), co-amoxiclav (26.3%), azithromycin (10.6%), and meropenem (10.3%). According to the World Health Organization AWaRe categorization, most (2260; 69.6%) of the antibiotics prescribed in this study belonged to the "Watch" group. Culture and sensitivity reports were available in 111 cases from one center. Only 18.9% of the patients were found to be co-infected with multi-drug-resistant bacteria (52.4% yield from sputum, 28.6% from urine, and 14.3% from blood).
Strict antibiotic prescribing policy and antibiotic stewardship should be implemented immediately to limit the future threat of antimicrobial resistance in countries such as Bangladesh.
在抗生素管理政策薄弱的热带国家,如孟加拉国,新型冠状病毒肺炎(COVID-19)患者不合理和不恰当使用抗生素可能有害。本研究旨在关注孟加拉国COVID-19患者的抗生素使用模式。
本前瞻性观察性研究于2020年7月至2021年6月在孟加拉国的五家三级医院进行。人口统计学资料、疾病严重程度和抗生素使用数据直接从患者的医院病历中收集。
共有3486例(94.4%)患者接受了至少一种抗生素治疗;3261例(93.6%)患者接受了单一抗生素治疗,225例(6.5%)患者接受了多种抗生素治疗。最常用的抗生素是头孢曲松(37.3%)、阿莫西林克拉维酸(26.3%)、阿奇霉素(10.6%)和美罗培南(10.3%)。根据世界卫生组织的AWaRe分类,本研究中开出的大多数抗生素(2260例;69.6%)属于“观察”组。来自一个中心的111例患者有培养和药敏报告。仅18.9%的患者被发现合并感染多重耐药菌(痰液培养阳性率为52.4%,尿液为28.6%,血液为14.3%)。
应立即实施严格的抗生素处方政策和抗生素管理,以限制孟加拉国等国家未来对抗菌素耐药性的威胁。